TTLTicker Tales
NSE: CIPLAHealthcare

Cipla

Cipla makes and sells generic and branded medicines - respiratory, chronic-disease and specialty drugs mainly - across India, the US, South Africa and other markets.

₹1,378.90▼−9.6%1 yearClosing price, 30 Oct 2026
  • P/E ~32x
  • Net profit -35% YoY (Q2FY27)
  • Debt-free, net cash ~₹10,526 cr
  • Promoter 29.2%, zero pledge
  • Down 16% from Oct'25 peak

Updated on 30 Oct 2026 · Data as of 30 Oct 2026

Get this report as a PDF free, straight to your inbox.

Snapshot

Share price
₹1,378.90
30 Oct 2026
52-week range
₹1,181.32 – ₹1,525.79
All-time peak
₹1,648.14
21 Oct 2025 · −16.3% from peak
Dividend yield
0.94%
Price history since
1996
About 30 years of prices
52-week low ₹1,181.32high ₹1,525.79

What's happening

Cipla reported Q2 FY27 (quarter ended Sep 30, 2026) results on October 27, 2026: revenue was roughly flat to slightly down (-2.4% YoY) at ₹7,404 crore, but EBITDA margin fell sharply to 18.7% from 25.0% a year ago, and consolidated net profit dropped by roughly a third. India sales hit a record high (+12% YoY), while US revenue was hurt by a supply disruption in lanreotide at manufacturing partner Pharmathen, which management does not expect to resolve this fiscal year. Management reiterated FY27 guidance of 18.5-20% EBITDA margin and a $1 billion annualised US exit run-rate, to be driven by new launches (Ventolin, generic Advair, plus three more pending launches).

In plain terms

Cipla sells medicines in India and abroad, and its India business is doing very well - its best quarter ever. But the company also depends on the US market for higher-margin products, and one of those products (lanreotide) is temporarily unavailable because of a manufacturing problem at a partner plant. That's why profit fell by about a third even though revenue barely moved - this is a margin story, not a sales collapse. The bigger question is whether new US product launches can replace what was lost.

Quarters

Q2 FY27 EBITDA margin improved 200 bps sequentially from Q1 FY27 but is still 630 bps lower than Q2 FY26 (18.7% vs 25.0%), so the margin reset is not yet reversed even though management says the trend is improving quarter on quarter. Reported net profit differs slightly by source - ₹851.51 crore per the company's own release reported by Free Press Journal versus ₹878 crore cited elsewhere - both point to a decline of roughly 35-37% YoY; treat the exact figure as directionally correct rather than precise to the rupee. North America revenue was $172 million, up $10 million sequentially, but down about 19% YoY in rupee terms because of the lanreotide disruption. Management guided FY27 EBITDA margin to 18.5-20% and effective tax rate to 27-27.5%.

Performance

Heads-up on splits: Cipla has split its shares or issued bonus shares before (most recently ×2.5 on 24 Apr 2006, 5-for-1 on 11 May 2004 and 3-for-1 on 18 Oct 1999). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.

Share price

−9.6% over 1 year

Returns by period

PeriodCiplaNifty 50Dr. Reddy's Laboratories
3 months−6.4%−5.5%+17.8%
1 year−9.6%−10.9%+13.2%
3 years+18.2%+20.8%+28.3%
5 years+58.0%+28.6%+45.5%

₹100 invested on 1 Nov 2021 became…

  • Cipla₹158
  • Nifty 50₹129
  • Dr. Reddy's Laboratories₹146

Over 1 year Cipla is down 9.6%, roughly tracking the Nifty (-10.9%) but far behind peer Dr Reddy's (+13.2%); the gap widens over 3 months and 3 years, where Cipla has underperformed both the index and the peer. Over 5 years Cipla has done well (+58% vs Nifty's +28.6% and the peer's +45.5%). There is no recent stock split, bonus or demerger in the supplied data (last split was in 2006), so the 16.3% fall from the October 2025 peak is a genuine price decline tied to the margin compression and regulatory issues described above, not a corporate-action artifact.

Dividend

Paid in the last 12 months

₹13.00 per share

Dividend yield

0.94%

Dividend yield is the last 12 months of dividends divided by today's share price. A 0.9% yield means every ₹100 of Cipla shares paid about ₹0.9 in dividends over the past year. Past payouts can change.

Recent dividends

DatePer share
5 Jun 2026₹13.00
27 Jun 2025₹16.00
2 Aug 2024₹13.00
21 Jul 2023₹8.50
8 Aug 2022₹5.00
9 Aug 2021₹5.00
19 Mar 2020₹4.00
31 Jul 2019₹3.00

Valuation

Cipla trades around 31-35x trailing earnings depending on the exact date and data source, close to the pharma industry median of roughly 31.9x. That is not statistically cheap or expensive versus peers - why it sits there is that the market is still pricing in the India franchise's strength and the promised US respiratory/peptide launches reaching a $1 billion run-rate; whether that premium is deserved depends on whether those launches arrive on schedule and whether the Pithampur plant's regulatory overhang gets resolved, neither of which is guaranteed.

Growth

Growth is split by geography. India grew 12% YoY to a record quarter - that is volume/prescription-led growth, the healthier kind. But the consolidated business actually shrank slightly (-2.4% revenue) and margins fell sharply because of the US lanreotide disruption, so at the group level this quarter was neither margin-led nor volume-led growth - it was a loss of a high-margin product category that masked the India strength.

Health

Cipla ended FY26 (March 2026) with a net cash position of about ₹10,526 crore against total debt of just ₹614 crore (mostly lease liabilities), so it is effectively debt-free. The business converts profit into cash comfortably; the real risk here is not financial (leverage) but operational/regulatory - a third-party manufacturing disruption that took out a US product, and an ongoing USFDA warning letter at the Pithampur (Indore) facility since November 2023, with a follow-up inspection in August 2026 still flagging seven observations.

Ownership

Promoters (the Hamied family, led by Yusuf Khwaja Hamied at 18.69%) held 29.21% as of September 2026 with zero pledged shares - a clean promoter holding. Institutional ownership is broad: FIIs ~20.25%, mutual funds ~20.78%, insurers ~11.69%. Not verified - could not confirm from available sources whether any individually tracked marquee investor holds a stake; treat any such claim as unconfirmed rather than assume absence.

The View

The one thing to watch

Whether Cipla's pipeline of new US launches (Ventolin, generic Advair, and three more pending launches) actually delivers the guided $1 billion annualised exit run-rate by the end of FY27, and whether the Pithampur plant clears its FDA warning letter, will show whether this margin reset is temporary or structural.

Strengths

  • +Net cash of roughly ₹10,526 crore against only ₹614 crore of debt (mostly leases) as of FY26-end - effectively debt-free
  • +India business posted its highest-ever quarterly revenue in Q2 FY27, up 12% YoY
  • +Zero promoter pledge on a 29.21% promoter holding as of September 2026
  • +A separate US-facing Cipla facility passed an FDA inspection with zero observations on October 23, 2026

Watchpoints

  • !EBITDA margin fell from 25.0% to 18.7% YoY in Q2 FY27 - a 630 bps compression
  • !US revenue fell about 19% YoY (in rupees) after a lanreotide supply disruption at manufacturing partner Pharmathen, which management says will not be resolved within FY27
  • !The Pithampur (Indore) plant remains under a USFDA warning letter issued in November 2023; an August 2026 follow-up inspection resulted in a Form 483 with seven observations, which blocks new product approvals from that site
  • !Consolidated net profit fell roughly 35-37% YoY in Q2 FY27 (reported as ₹851.51 crore or ₹878 crore depending on source) - the margin reset has not yet reversed despite management's guidance

How sure are we about the data? · Moderate

Q2 FY27 revenue (₹7,404 crore) and EBITDA margin (18.7%) were consistent across multiple sources. Reported net profit varied between sources (₹851.51 crore vs ₹878 crore) - both imply a ~35-37% YoY decline, but the exact rupee figure is not fully reconciled here. Net cash/debt figures are from the FY26 (March 2026) annual results. Promoter holding and pledge data are from September 2026 shareholding-pattern trackers (Trendlyne, MarketsMojo) rather than a direct BSE/NSE filing check. Presence of any marquee individual investor on the register could not be verified.

Keep it for later

Get the Cipla report as a PDF

The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.

Free. We use your email only to send this report and the newsletter.

Share this X LinkedIn WhatsApp

← All Nifty 100 companies

Reports are refreshed every quarter, about three days after each company announces its results.

Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 30 Oct 2026.